Chenguang Biotech announced that from the date of review and approval of the 2025 annual shareholders' meeting until the 2026 annual shareholders' meeting, the balance of the financing business should not exceed 7 billion yuan, and the guarantee balance for the subsidiary should not exceed 2.8 billion yuan. As of the disclosure date of the announcement, the holding subsidiary Bazhou Shengyuan had repaid the loan of 200 million yuan, and the company reduced the corresponding guarantee obligation; the wholly-owned subsidiary Shache Chenguang received a credit of 30 million yuan from China Merchants Bank, and the company provided a joint and several liability guarantee for it. After the change, the company and subsidiaries resolved a total guarantee amount of 2.8 billion yuan, and signed an agreement guarantee amount of 1,368 billion yuan, accounting for 40.36% of the latest audited net assets, with no overdue external guarantees.

Chenguang Biotech announced that from the date of review and approval of the 2025 annual shareholders' meeting until the 2026 annual shareholders' meeting, the balance of the financing business should not exceed 7 billion yuan, and the guarantee balance for the subsidiary should not exceed 2.8 billion yuan. As of the disclosure date of the announcement, the holding subsidiary Bazhou Shengyuan had repaid the loan of 200 million yuan, and the company reduced the corresponding guarantee obligation; the wholly-owned subsidiary Shache Chenguang received a credit of 30 million yuan from China Merchants Bank, and the company provided a joint and several liability guarantee for it. After the change, the company and subsidiaries resolved a total guarantee amount of 2.8 billion yuan, and signed an agreement guarantee amount of 1,368 billion yuan, accounting for 40.36% of the latest audited net assets, with no overdue external guarantees.